Many patients navigating cancer treatment seek therapies that can support strength, energy, and quality of life during chemotherapy, radiation, immunotherapy, or hormonal therapy. One of the most widely used complementary treatments in European integrative oncology is mistletoe extract, derived from Viscum album L.
For decades, mistletoe has been integrated into oncology care in Germany and Switzerland. In the United States, interest has grown steadily as patients and clinicians explore evidence-informed supportive therapies. Below is a comprehensive, patient-friendly review of how mistletoe is used, what the science suggests, and what two important modern trials — including one conducted in the U.S. and the large MISTRAL trial in Europe — tell us about its role in cancer care.
What Is Mistletoe Therapy?
European white-berry mistletoe is an evergreen plant that grows semi-parasitically on trees. Extracts from the plant are processed into standardized injectable preparations used in oncology settings. These preparations contain biologically active compounds such as mistletoe lectins, viscotoxins, flavonoids, and polysaccharides.
Mistletoe therapy is typically administered as subcutaneous injections several times per week. Dosing is individualized and often gradually increased to achieve a mild, desired immune response — commonly seen as slight redness or warmth at the injection site. In some specialized integrative oncology clinics, intravenous mistletoe is also administered under medical supervision, particularly when higher systemic exposure is desired.
Importantly, mistletoe is not used as a replacement for conventional treatment. In integrative oncology, it is positioned as a supportive therapy — intended to complement standard cancer care and improve the lived experience of treatment.
Biological Rationale: Why Has Mistletoe Been Studied?
Laboratory research has shown that mistletoe extracts can influence immune signaling and tumor-related pathways. Mistletoe lectins, in particular, have been studied for their ability to:
• Stimulate natural killer (NK) cells
• Activate certain T-lymphocytes
• Influence cytokine production
• Affect tumor cell apoptosis (programmed cell death)
• Potentially inhibit angiogenesis in some models
These preclinical findings helped generate interest in whether mistletoe might improve symptom control, enhance immune resilience, or even influence cancer progression. However, laboratory activity does not automatically translate into clinical benefit. Well-designed human trials are necessary to determine real-world impact.
Clinical Research in the United States
While mistletoe has a long tradition in Europe, high-quality clinical research in the United States has been more limited. One of the most important U.S.-based investigations was a Phase I clinical trial conducted at Johns Hopkins Hospital Sydney Kimmel Cancer Center (1), evaluating intravenous mistletoe in patients with advanced solid tumors.
Purpose of the U.S. Phase I Trial
The primary goal of this trial was safety — not anticancer efficacy. Phase I studies are designed to determine:
• Appropriate dosing
• Safety and tolerability
• Side-effect profile
• Pharmacologic behavior
Patients enrolled in the study had advanced cancers that had progressed despite prior therapies. This population typically has limited treatment options and advanced disease burden.
What Did the U.S. Study Find?
The trial demonstrated that intravenous mistletoe could be administered with a manageable safety profile under close supervision. Reported side effects were generally mild to moderate and included:
• Fever
• Chills
• Fatigue
• Local or systemic inflammatory responses
Importantly, no unexpected severe toxicities emerged. This was a key finding, as intravenous dosing represents higher systemic exposure than traditional subcutaneous administration.
Although the study was not powered to determine effectiveness, some patients experienced stable disease, and a small number showed minor tumor reductions. Quality-of-life measures demonstrated trends toward improvement in certain domains, though these findings were exploratory.
What Does This Mean?
The U.S. trial established that intravenous mistletoe could be safely studied within an American oncology framework. It did not prove anticancer benefit, but it provided an important foundation for future trials.
From an integrative oncology perspective, the U.S. data suggest that mistletoe can be administered safely in experienced hands and may have potential supportive effects worth further investigation.
Pancreatic Cancer Research: The MAPAC Study
Interest in mistletoe intensified following the MAPAC trial (2), an open-label randomized study in patients with advanced pancreatic cancer who were not receiving chemotherapy.
In this study:
• 220 patients were randomized
• One group received subcutaneous mistletoe plus best supportive care
• The control group received best supportive care alone
Median survival was 4.8 months in the mistletoe group compared with 2.7 months in the control group. Patients receiving mistletoe also gained weight and reported improvements across multiple quality-of-life scales.
These findings were encouraging — particularly in cancer with historically limited treatment options. However, the study was not blinded, meaning both patients and physicians knew who was receiving mistletoe. This can introduce bias, especially in subjective measures such as symptom reporting.
To address these limitations, researchers designed a more rigorous study.
The MISTRAL Trial: A Gold-Standard Evaluation
The MISTRAL trial (3) was a double-blind, placebo-controlled randomized study conducted in Swedish oncology centers. This design represents the highest standard of clinical evidence because:
• Neither patients nor clinicians know who receives active treatment
• Placebo controls reduce expectation bias
• Randomization balances patient characteristics
Who Was Included?
Nearly 300 patients with advanced exocrine pancreatic cancer were enrolled. Participants were stratified based on treatment sites and whether they were eligible for palliative chemotherapy.
Patients were randomly assigned to receive:
• Mistletoe extract injections three times per week
• Placebo injections
Treatment continued for up to nine months in addition to comprehensive cancer care.
Primary and Secondary Endpoints
The primary outcome was overall survival.
Secondary outcomes included global health-related quality of life, assessed repeatedly over nine months using the EORTC QLQ-C30 instrument.
Results of the MISTRAL Trial
The findings were clear:
• No statistically significant improvement in overall survival
• Median survival was 7.8 months in the mistletoe group versus 8.3 months in placebo
• No meaningful difference in global quality-of-life scores
• Similar rates of systemic adverse events
The only consistent difference was a higher rate of local injection-site reactions in the mistletoe group (66% vs. 1%).
Interpretation
The MISTRAL trial concluded that mistletoe extract was unlikely to produce a clinically meaningful survival benefit or improvement in global quality of life when added to standard treatment for advanced pancreatic cancer.
This study is particularly important because it addressed limitations seen in earlier open-label research.
Why Do Studies Show Different Results?
When patients encounter conflicting headlines about mistletoe, it can feel confusing. Several factors may explain why results vary:
1. Study Design Differences
Open-label studies are more vulnerable to expectation bias. Double-blind studies reduce this influence.
2. Differences in Background Treatment
Earlier studies often involved patients not receiving chemotherapy. Modern trials include patients undergoing more advanced systemic therapies.
3. Disease Stage and Biology
Advanced, heavily pretreated cancers may respond differently than earlier-stage disease.
4. Treatment Goals
Some studies focus on symptom improvement rather than survival. Measuring quality of life can be complex and influenced by many variables.
Where Does Evidence Stand Today?
When looking at the full body of research, several conclusions can be drawn:
• Mistletoe therapy appears generally safe under medical supervision.
• Evidence for improved quality of life is stronger than evidence for survival benefit.
• High-quality randomized trials, such as MISTRAL, have not demonstrated a survival advantage in advanced pancreatic cancer.
• U.S. data support safety but remain preliminary regarding effectiveness.
For other cancer types — including breast, colorectal, lung, and gynecologic cancers — observational studies and smaller trials suggest possible improvements in fatigue, appetite, and treatment tolerability. However, methodological variability limits firm conclusions about survival impact.
How Mistletoe Fits into Integrative Oncology
Integrative oncology focuses on combining conventional treatment with evidence-informed supportive therapies that enhance resilience and patient wellbeing.
In carefully selected patients, mistletoe may be considered as part of a broader supportive plan that includes:
• Nutritional optimization
• Exercise and metabolic support
• Stress reduction and mind–body therapies
• Inflammatory and immune regulation strategies
The emphasis is not on replacing chemotherapy or immunotherapy, but on supporting the whole person during treatment.
The Bottom Line for Patients
Mistletoe therapy has a long history in European oncology and an expanding research base. Early open-label studies suggested possible survival and quality-of-life benefits in certain cancers, including pancreatic cancer. However, more rigorous trials — particularly the MISTRAL study — did not confirm a survival or global quality-of-life advantage in advanced pancreatic cancer.
In the United States, early-phase research has demonstrated acceptable safety and potential signals worth further study, but definitive efficacy data remain limited.
For many patients, the value of mistletoe lies in its supportive potential rather than as a primary anticancer therapy. Decisions about its use should be individualized, medically supervised, and coordinated with your oncology team.
Schedule a consultation
For those seeking advanced supportive care to enhance recovery and sustain long-term wellness, a personalized consultation with our experienced integrative oncology team can help determine the therapies that best support your unique goals and medical history.
At CAREVIVOR, we provide an oncologist-directed, holistic wellness program crafted exclusively for cancer survivors. Our approach harmonizes the precision of conventional oncology with evidence-informed integrative strategies, empowering patients to move beyond survivorship toward renewed vitality, resilience, and long-term wellness.
Dr. Young Lee, trained and certified by Physician’s Association for Anthroposophic Medicine (PAAM), brings expertise in mistletoe therapy as part of our tailored supportive care offerings.
Call 410-740-7444 to schedule your personalized consultation.
REFERENCES:
1. Paller CJ, Wang L, Fu W, Kumar R, Durham JN, Azad NS, Laheru DA, Browner I, Kachhap SK, Boyapati K, Odeny T, Armstrong DK, Meyer CF, Gaillard S, Brahmer JR, Page I, Wang H, Diaz LA Jr. Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer Res Commun. 2023 Feb 28;3(2):338-346. doi: 10.1158/2767-9764.CRC-23-0002. PMID: 36860652; PMCID: PMC9973409.
2. Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. 2013 Dec;49(18):3788-97. doi: 10.1016/j.ejca.2013.06.043. Epub 2013 Jul 24. PMID: 23890767.
3. Wode K, Kienle GS, Björ O, Fransson P, Sharp L, Elander NO, Bernhardson BM, Johansson B, Edwinsdotter Ardnor C, Scheibling U, Hök Nordberg J, Henriksson R. Mistletoe Extract in Patients With Advanced Pancreatic Cancer: a Double-Blind, Randomized, Placebo-Controlled Tial (MISTRAL). Dtsch Arztebl Int. 2024 May 31;121(11):347-354. doi: 10.3238/arztebl.m2024.0080. PMID: 38915151; PMCID: PMC11539882.